Highbridge Capital Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 36.5% during the first quarter, Holdings Channel reports. The firm owned 77,421 shares of the medical instruments supplier’s stock after selling 44,458 shares during the period. Highbridge Capital Management LLC’s holdings in Becton, Dickinson and were worth $14,202,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in BDX. Guardian Life Insurance Co. of America raised its position in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 6 shares during the last quarter. Wellington Shields & Co. LLC raised its position in shares of Becton, Dickinson and by 0.3% in the first quarter. Wellington Shields & Co. LLC now owns 2,534 shares of the medical instruments supplier’s stock worth $465,000 after buying an additional 8 shares during the last quarter. Parkside Financial Bank & Trust raised its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Capital Investment Advisors LLC raised its position in shares of Becton, Dickinson and by 0.7% in the first quarter. Capital Investment Advisors LLC now owns 2,412 shares of the medical instruments supplier’s stock worth $442,000 after buying an additional 17 shares during the last quarter. Finally, North Star Investment Management Corp. raised its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) traded up 0.34% on Thursday, hitting $198.52. The stock had a trading volume of 263,197 shares. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The company’s 50 day moving average is $198.62 and its 200-day moving average is $187.41. The firm has a market capitalization of $45.18 billion, a price-to-earnings ratio of 57.49 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the previous year, the firm posted $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post $9.45 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

WARNING: “Becton, Dickinson and Company (BDX) Shares Sold by Highbridge Capital Management LLC” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-highbridge-capital-management-llc/1470870.html.

A number of research analysts have commented on BDX shares. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $210.00 to $180.00 in a research report on Friday, June 30th. Royal Bank Of Canada reiterated a “hold” rating and issued a $177.00 price objective on shares of Becton, Dickinson and in a research report on Thursday, April 13th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $194.69.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.